Best Neurology Companies in Boston, United States
The 60 best Neurology companies in Boston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Seaport Therapeutics.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Boston
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Seaport Therapeutics Developer of therapeutics to treat neuropsychiatric disorders | $325M | 20 mo ago | — | 2020 | Steven Paul Co-Founder | — | 1 award |
| 2 | Rapport Provider of neuro medicines development and communication services | $250M | 34 mo ago | 25 | 2022 | David Bredt Founder | — | — |
| 3 | Centessa Pharmaceuticals Developer of therapeutic programs addressing unmet needs in various disease areas | $250M | 64 mo ago | 83 83 → 157 (+89%) | 2021 | — | — | — |
| 4 | Blue Rock Therapeutics Stem cell therapies for cardiovascular and neurological diseases | $225M | 114 mo ago | 138 | 2016 | — | — | — |
| 5 | CervoMed Developer of therapeutics for neurodegenerative diseases | $209M | 16 mo ago | 13 13 → 20 (+54%) | 2001 | John Alam Co-Founder & CEO | — | — |
| 6 | Eliem Therapeutics Developer of non-opioid therapies for treating chronic pain | $171M | 62 mo ago | 30 | 2018 | Valerie Morisset Co-Founder | — | — |
| 7 | Acetylon Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $138M | 155 mo ago | 37 | 2008 | Marc Cohen Co-Founder | — | — |
| 8 | AZTherapies Small molecule drugs and drug delivery systems for Alzheimer's disease. | $131M | 69 mo ago | 10 | 2011 | — | 74 patents Patents concentrated in health & consumer products | — |
| 9 | Atalanta Therapeutics Developer of RNAi therapeutics to treat neurodegenerative diseases | $110M | 17 mo ago | 62 | 2019 | Neal Aronin Co-Founder | — | — |
| 10 | Praxis Medicines Developer of therapies to treat brain disorders | $110M | 74 mo ago | 82 | 2015 | — | 484 patents Small‑molecule ion channel modulators for neurological disorder therapeutics | — |
| 11 | Nido Biosciences Developer of therapeutics for neurological disorders | $109M | 37 mo ago | 26 | 2018 | Jeremy Springhorn CEO | 38 patents Small-molecule androgen receptor modulators (indole/bicyclic chemotypes) | — |
| 12 | PureTech Health Developer of immunotherapeutics for multiple diseases | $107M | 35 mo ago | 171 | 2005 | Robert Langer Co-Founder | — | — |
| 13 | SAGE Therapeutics Developer of drug candidates for the treatment of rare CNS disorders | $106M | 65 mo ago | 487 | 1971 | Barry Greene CEO | 1,810 patents Neuroactive steroid compounds and formulations for treating central nervous system disorders | — |
| 14 | Newleos Developer of oral small molecules for neuropsychiatric conditions treatment | $94M | 17 mo ago | — | 2009 | Federico Bolognani Chief Medical Officer and co-Founder | — | — |
| 15 | Karuna Therapeutics Developer of therapies for the treatment of psychosis and cognitive impairment | $81M | 87 mo ago | 339 | 2009 | Steven Paul CEO | — | — |
| 16 | Centrexion Developer of drugs for chronic pain management | $66M | 13 mo ago | 14 | 2013 | Sol Barer Founder & Chairman | — | — |
| 17 | Elevian Developer of regenerative therapies for treating age-related diseases | $61M | 57 mo ago | 6 | 2017 | Mark Allen Co-Founder & CEO | 7 patents Peptide-based pharmaceutical compositions for acute stroke treatment and neuroprotection. | — |
| 18 | Flex Pharma Developer of therapeutics for neuromuscular disorders | $56M | 142 mo ago | 34 | 2014 | — | — | — |
| 19 | OcuTerra Therapeutics Developer of eye drop to treat diabetic eye disease | $40M | 30 mo ago | 4 | 2020 | — | — | — |
| 20 | Sensorium Therapeutics Developer of therapeutics for psychiatric and neurological disorders | $30M | 14 mo ago | 23 | 2021 | Alex Simon Co-Founder | — | — |
| 21 | Aphios Developer of therapeutic products and enabling technology platforms for healthcare | $17M | 21 mo ago | 12 | 1993 | — | 81 patents Pathogen inactivation in blood products and nanotech drug delivery for cannabinoids | — |
| 22 | Tal Medical Neurostimulation based treatment for psychiatric disorders | $15M | 134 mo ago | 11 | 2011 | — | — | — |
| 23 | Micro Leads Precision neuromodulation therapies using minimally-invasive, high-resolution devices for nervous system… | $15M | 14 mo ago | 12 | 2014 | — | — | — |
| 24 | Modulight Biotherapeutics Developer of an optogenetic platform targeting pathological neural activity to restore balance | $12M | 7 mo ago | — | 2022 | Ofer Yizhar Co-Founder & CSO | — | 1 award |
| 25 | Boston Immune Technologies & Therapeutics Developer of immune-based therapies for treating cancer and infectious diseases | $10M | 16 mo ago | 6 | 2011 | — | — | — |
| 26 | Psy Therapeutics Developer of therapeutics for CNS disorders | $10M | 54 mo ago | — | 2018 | Maurizio Fava Co-Founder | — | — |
| 27 | Zeta Surgical Developer of AI-based navigation and robotics system for surgeries | $8M | 32 mo ago | 7 | — | Jose Amich Co-Founder & CEO | — | 4 partnerships |
| 28 | Cure Rare Disease Developer of therapeutics to treat rare neuromuscular diseases | $8M | 17 mo ago | 21 | 2017 | Rich Horgan Founder & CEO | — | — |
| 29 | Blue Therapeutics Developer of small molecule drugs for neurological disorders | $7M | 62 mo ago | 4 | 2014 | Ajay Yekkirala Co-Founder & CSO | — | — |
| 30 | Rebion Provider vision scanning devices to diagnose brain diseases | $7M | 15 mo ago | 13 | 2009 | — | — | — |
| 31 | Prexa Pharmaceuticals Small molecule drugs for CNS diseases | $6M | 182 mo ago | — | 2006 | Charlie Cohen CEO | — | — |
| 32 | LikeMinds Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases | $6M | 60 mo ago | 7 | 2008 | Azmat Yusuf Chairman & CEO | 27 patents Neurodiagnostic imaging agents and accelerated brain delivery of therapeutic compounds | — |
| 33 | BrainSpec Web-based Magnetic Resonance Spectroscopy (MRS) software platform | $4M | 106 mo ago | — | 2015 | Alexander Lin Co Founder | 3 patents Integrating brain imaging and spectroscopy data for diagnostic and research analysis. | — |
| 34 | Entheos Labs Developer of psychedelic-based treatments for mental health disorders | $4M | 21 mo ago | — | 2022 | Tristan Edwards Co-Founder & CEO | — | — |
| 35 | Functional Neuromodulation Deep Brain Stimulation of the Fornix (DBSf) technology for Alzheimer's disease treatment | $3M | 171 mo ago | 7 | 2010 | Andres Lozano Founder | — | — |
| 36 | Resilience Therapeutics Therapeutics for stress disorders using its proprietary drug discovery engine | $3M | 124 mo ago | 8 | 2014 | Jeff Sabados CEO & Co-Founder | — | — |
| 37 | PathMaker Neurosystems Neuromodulation company pioneering non-invasive treatments for ALS and neurological disorders | $3M | 25 mo ago | 4 | 2014 | — | 6 patents Multi-site neurostimulation control systems for precise brain stimulation | 1 partnership |
| 38 | Cerevel Therapeutics 🦄 Developer of therapeutics for neurological and neuropsychiatric disorders | $3M | 13 mo ago | 199 | 2018 | Tony Coles CEO | — | — |
| 39 | Magnendo Developer of a device for the treatment of neurovascular diseases | $2M | 25 mo ago | — | 2024 | Yoonho Kim Founder & CEO | 2 patents Automated guidewire steering systems for minimally invasive cardiovascular procedures | — |
| 40 | AbFero Pharmaceuticals Developer of oral iron chelators for the treatment of iron overload diseases | $2M | 63 mo ago | 3 | 2016 | Raymond Bergeron Co-Founder & CSO | — | — |
| 41 | BioROSA Technologies Developer of blood tests for early detection of Autism Spectrum Disorder | $2M | 43 mo ago | 6 | 2018 | John Slattery Co-Founder & CEO | — | — |
| 42 | Klogenix Developer of therapeutics for the treatment of age-related diseases | $1M | 85 mo ago | — | 2019 | Carmela Abraham Founder | 10 patents Biotech tools for gene expression modulation and DNA‑binding protein therapeutics | — |
| 43 | Alexis Bio Developer of cell therapies to treat common and rare diseases | $1M | 63 mo ago | 3 | 2016 | Jon Adkins Co-Founder | — | — |
| 44 | RBI Medical Provider of a device for the treatment of pelvic health conditions | $1M | 38 mo ago | 7 | 2019 | Mario Ortega Co-Founder & CTO | — | — |
| 45 | OnPoint Surgical Provider of spinal imaging technology | $200K | 10 mo ago | 14 | 2016 | Philipp Lang Co-Founder & CEO | — | — |
| 46 | Neural Dynamics Technologies Developer of neural interface tools to analyze brain function | $125K | 24 mo ago | 5 | 2018 | Ingrid Welie Founder & CEO | — | — |
Top 12 Neurology companies in Boston
#1
Public · Boston, Massachusetts · founded 2001 · 13 employees$208.9Mraised▾
Developer of therapeutics for neurodegenerative diseases. It offers a lead product neflamapimod an oral, selective small molecule inhibitor of the protein kinase p38 alpha for treating dementia with Lewy bodies and Alzheimer’s disease.
- Mar 2025Grant (prize money)$21.1M
- Mar 2025Grant (prize money)$21.1M
- Mar 2024Post IPO$149.4M
- Feb 2023Grant (prize money)$15M
#2
Public · Boston, Massachusetts · founded 2013 · 14 employees$65.7Mraised▾
Centrexion has developed non-opioid, non-surgical treatments for chronic pain management. The company's lead candidate CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic pain due to knee osteoarthritis (phase III). The other products include CNTX-0290 (somatostatin SSTR4 agonist) for pain (phase I), CNTX-6970 (cytokine CCR2 antagonist) to treat inflammatory pain (phase II), CNTX-2022 (lidocaine gel) to treat superficial pain (phase I), and CNTX-6016 (CB2 agonist) to treat neuropathic pain (phase I).
- May 2025Grant (prize money)$6.6M
- Jan 2025Grant (prize money)$6.6M
- Dec 2023Post IPO$3.3M
- Nov 2023Post IPO$2.3M
#3
Seed · Boston, Massachusetts · founded 2022$12.2Mraised▾
Developer of an optogenetic platform targeting pathological neural activity to restore balance. The platform precisely targets pathological neural activity when and where it occurs. It aims to restore equilibrium within the nervous system through targeted intervention.
- Nov 2025Seed$12.2M
#4
Public · Boston, Massachusetts · founded 2020$325Mraised▾
Developer of therapeutics to treat neuropsychiatric disorders. The company is advancing a pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph Technology which leverages the lymphatic system to create medicines building on clinically validated mechanisms. The company's product line include SPT-300 which is an oral prodrug of allopregnanolone, an endogenous neurosteroid, in development for the treatment of anxious depression.
- Oct 2024Series B$225M
- Apr 2024Series A$100M
#5
Series B · Boston, Massachusetts · founded 2019 · 62 employees$110Mraised▾
Developer of RNAi therapeutics to treat neurodegenerative diseases. The company's proprietary branched siRNA enables RNA interference to be deployed as a therapeutic throughout the brain and spinal cord. This platform helps in the treatment of Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative diseases.
- Jan 2025Series B$97M
- Jan 2021Series A$110M
#6
Series A · Boston, Massachusetts · founded 2021 · 23 employees$30Mraised▾
Developer of therapeutics for psychiatric and neurological disorders. The company leverages a Biodynamic discovery platform to develop plant-based compounds for CNS disorders. The lead candidates of the company are SENS-01 and SENS-02 for anxiety, depression, and neurological disorders.
- May 2025Grant (prize money)$2M
- Jan 2025Series A$26.8M
- Dec 2023Grant (prize money)$502.5K
- Sep 2022Series A$30M
#7
Series A · Boston, Massachusetts · founded 2009$93.5Mraised▾
Developer of oral small molecules for neuropsychiatric conditions treatment. It focuses on neuropsychiatric mechanisms of action that aim to reduce side effects. Its molecules target GABAA-γ1, V1a, TAAR1 and GABAA-α5, with potential in treating anxiety and substance use disorders.
- Feb 2025Series A$93.5M
#8
Seed · Boston, Massachusetts · founded 2014 · 12 employees$14.5Mraised▾
Precision neuromodulation therapies using minimally-invasive, high-resolution devices for nervous system interfaces. The company develops a closed-loop platform for precision reading and writing into the nervous system. They offer next-generation therapeutic platforms for high-resolution spinal cord stimulation, peripheral nerve stimulation, and brain-computer interfaces. Their expertise lies in programmable electrodes, shape-memory, and high-resolution electrodes and neurostimulators hardware and software systems. The technology enables precision and personalized therapies, interfacing with the spinal cord, brain, vagus nerve, and peripheral nerves. The therapeutic platform is being developed for treatments where low-resolution neuromodulation therapies have failed, addressing chronic pain management and sensory-motor paralysis. This is a B2B tech company focused on medical devices and software.
- Apr 2025Grant (prize money)$9.8M
- Sep 2023Grant (prize money)$400K
- Sep 2017Grant (prize money)$1.1M
- Sep 2017Grant (prize money)$1.2M
#9
Seed · Boston, Massachusetts · founded 2009 · 13 employees$7.5Mraised▾
Provider vision scanning devices to diagnose brain diseases. The company's technology (Neural Performance Scanning) uses a laser to scan a patient's retinas to detect amblyopia automatically with high sensitivity. Since the original PVS device, the company has been developing applications for the detection of traumatic brain injury in addition to amblyopia. It is available on Android platforms.
- Mar 2025Grant (prize money)$1M
- Apr 2022Grant (prize money)$1M
- May 2019Seed$7.5M
- Jun 2012Grant (prize money)$100K
#10
Series A · Boston, Massachusetts · founded 2011 · 6 employees$10Mraised▾
Developer of immune-based therapies for treating cancer and infectious diseases. The company has developed therapeutics for targeting the tumor necrosis factor receptor 2 oncogene and acute infectious disease. Also, has developed antibodies that target CD-40 a tumor necrosis factor receptor that mediates T-dependent B cell responses and efficient T cell priming for autoimmune diseases.
- Feb 2025Grant (prize money)$1.2M
- Feb 2025Grant (prize money)$1.2M
- Aug 2023Grant (prize money)$298K
- Sep 2021Grant (prize money)$4M
#11
Funding Raised · Boston, Massachusetts · founded 1993 · 12 employees$16.9Mraised▾
Developer of therapeutic products and enabling technology platforms for healthcare. The company focuses on advancing health through sustainable science, integrating green enabling technology platforms with biotechnology. These platforms improve drug discovery and manufacturing, nanotechnology drug delivery, and pathogen safety. The company develops therapeutics for cancer, infectious diseases, and central nervous system disorders.
- Sep 2024Grant (prize money)$504.7K
- Sep 2023Grant (prize money)—
- Jul 2023Grant (prize money)$335.7K
- Mar 2023Grant (prize money)$600K
#12
Funding Raised · Boston, Massachusetts · founded 2017 · 21 employees$7.7Mraised▾
Developer of therapeutics to treat rare neuromuscular diseases. The company is developing a pipeline of drugs for Duchenne muscular dystrophy, Limb-girdle muscular dystrophy 2b, Limb Girdle Muscular Dystrophy 2, and Gene-related amyotrophy.
- Feb 2025Grant (prize money)$5.7M
- 2023Grant (prize money)$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neurotech in Boston is moving
A read on the academic research around Neurotech in Boston — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 178 papers.
Boston University and Boston Scientific lead Boston's neurotech research, predominantly advancing neurological disorder treatments and neural engineering with an optimistic tone, though concern remains a minor thread.
- Boston University73
- Boston Scientific41
- Boston Scientific25
- Boston Children\'s Hospital25
- VA Boston Healthcare System10
- Deep brain stimulation3→8
- Stimulation2→6
- Neuroscience5→8
- Optogenetics1→3
- Neurostimulation1→3
- Deep brain stimulation12→33
- Neuroscience5→19
- Stimulation6→15
- Parkinson's disease5→11
- Neurostimulation7→13
- Deep brain stimulation3→9
- Parkinson's disease2→3
- Neurostimulation2→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.